Related Experiment Video
Updated: Oct 15, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Early detection of gastric cancer using DNA features in red blood cells, with multicenter validation
Xingyun Yao1, Haobo Sun2, Cheng Fang3
1College of Life Sciences, Zhejiang University, Hangzhou, Zhejiang, China; Key Laboratory of Growth Regulation and Translational Research of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, Zhejiang 310030, China.
Background:
Early detection of gastric cancer (GC) is limited by invasive endoscopy and poor sensitivity of blood-based biomarkers. Red blood cells (RBCs), the most abundant cells in the circulation, are anucleate but can retain DNA remnants that have been associated with pathological stress. Here, we report a non-invasive strategy for GC detection based on genome-wide profiling of DNA remnants retained in RBCs (rbcDNA).
Methods:
We performed shallow whole-genome sequencing of rbcDNA from 1-2 mL of peripheral blood of 865 individuals, including 434 treatment-naive GC patients and 431 non-GC controls with benign gastric conditions. In the discovery cohort, we identified 1,000 reproducible rbcDNA read-depth features distinguishing GC from non-cancer states. A machine learning classifier based on dimensionally reduced GC-associated rbcDNA features was trained in the discovery cohort (n = 435), with the cutoff fixed at 90% specificity, and evaluated in a test cohort (n = 109) and three independent multicenter validation cohorts (n = 321).
Findings:
The classifier achieved the areas under the receiver operating characteristic curve (AUCs) of 84% in nested cross-validation of the discovery cohort and 95% in the test cohort. Across three hospital-based multicenter validation cohorts, performance remained consistent, with 83%-90% overall sensitivity and 82%-89% sensitivity for stage I GC. Additionally, the classifier distinguished early-stage GC from precancerous lesions and other tumors and detected ∼80% of GC cases negative for tumor markers.
Conclusions:
These findings demonstrate the potential of rbcDNA as a non-invasive biomarker for early-stage GC detection.
Funding:
This work was supported by the Key Research and Development Program of Zhejiang Province (2026C02A1176 and 2024C03170).

